MetaTrader
  • Mercati
  • Grafici & Idee
  • Algo
  • Notizie
  • Store
  • Broker
  • Scarica
  • Calendario Economico
  • Segnali di Trading
  • Terminale Web
  • English English
  • Русский Русский
  • 中文 中文
  • Español Español
  • Português Português
  • 日本語 日本語
  • Deutsch Deutsch
  • 한국어 한국어
  • Français Français
  • Türkçe Türkçe
Gain Therapeutics, Inc. Common Stock

GANX

#3291
Gain Therapeutics, Inc. Common Stock
2.61
+7.85%
Settore:
Base:
Valuta di Profitto:
Intervallo Giornaliero
2.61
2.61
Intervallo Annuale
1.41
4.34
Variazione giornaliera
+7.85%
Variazione Mensile
+26.70%
Variazione di 6 mesi
+38.83%
Variazione Annuale
+30.50%
Chiusura Precedente
2.42
Open
2.61
Bid
Ask
Low
2.61
High
2.61
Volume
16
  1. Mercati
  2. Mercato Azionario Statunitense
  3. Salute
  4. GANX
Open full chart

Financials

Overview Estratto Conto Statistics Dividends
Quarterly Annual
Value 2021202220232024 TTM

Notizie

Investing Investing
GANX
2026.01.06
Gain Therapeutics riporta riduzione dell’81% in biomarcatore del Parkinson
Investing Investing
GANX
2026.01.06
Gain Therapeutics reports 81% reduction in Parkinson’s biomarker
Benzinga Benzinga
GHRS RGC SIDU CNTX PBF
2026.01.05
Why GH Research Shares Are Trading Higher By 18%; Here Are 20 Stocks Moving Premarket - BioAtla (NASDAQ:BCAB), ChowChow Cloud Internatio (AMEX:CHOW)
Zacks Zacks
GANX
2025.12.22
Gain Therapeutics (GANX) Upgraded to Buy: Here's Why
Investing Investing
GANX
2025.12.22
Roth/MKM alza il target di prezzo delle azioni Gain Therapeutics a $10
Investing Investing
AMZN NVDA MSFT PG CVX
2025.12.18
U.S. stocks higher at close of trade; Dow Jones Industrial Average up 0.14%
Zacks Zacks
EHAB GANX
2025.12.18
Is Enhabit, Inc. (EHAB) Stock Outpacing Its Medical Peers This Year?
Zacks Zacks
GANX
2025.12.08
Here's Why Gain Therapeutics, Inc. (GANX) is a Great Momentum Stock to Buy
Investing Investing
GANX
2025.12.01
H.C. Wainwright conferma il rating Buy su Gain Therapeutics prima dei dati clinici
Investing Investing
GANX
2025.12.01
H.C. Wainwright reiterates Buy rating on Gain Therapeutics stock ahead of trial data
Investing Investing
GANX
2025.11.28
Gain Therapeutics presenta supplemento al prospetto per offerta di titoli da 35,5 milioni di dollari
Investing Investing
GANX
2025.11.28
Gain Therapeutics files prospectus supplement for $35.5 million stock offering

Mercati

  • Mercato Azionario Americano
  • Valute
  • Criptovalute
  • Metalli
  • Materie Prime

Grafici & Idee

  • Idee di Trading
  • Idee Educative
  • Grafici

MQL5 Community

  • Market
  • Segnali
  • Forum
  • Articoli
  • CodeBase

Notizie

  • Mercato Azionario Americano
  • Valute
  • Criptovalute
  • Metalli
  • Materie Prime

Broker

  • Tutti i Broker
  • Forex
  • Azioni
  • Metalli
MetaTrader 5
MQL5 Channels
Economic Calendar
Esclusione di Responsabilità e Informativa sui Rischi Termini di Utilizzo Contatti e richieste Legale
Copyright 2000-2026, MetaQuotes Ltd